002422 Stock Overview
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Sichuan Kelun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥31.62 |
| 52 Week High | CN¥35.49 |
| 52 Week Low | CN¥21.60 |
| Beta | 0.069 |
| 11 Month Change | -3.48% |
| 3 Month Change | -2.01% |
| 1 Year Change | 12.53% |
| 33 Year Change | 68.46% |
| 5 Year Change | 32.97% |
| Change since IPO | 111.65% |
Recent News & Updates
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Recent updates
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors
Nov 17Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet
Oct 28Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement
Sep 22Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?
Aug 16Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?
Jul 12Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares
Jun 11An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued
May 21Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem
May 02If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity
Mar 19Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Mar 04These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely
Feb 27Shareholder Returns
| 002422 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.3% | -1.3% | -3.4% |
| 1Y | 12.5% | -3.4% | 6.1% |
Return vs Industry: 002422 exceeded the CN Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 002422 exceeded the CN Market which returned 6.1% over the past year.
Price Volatility
| 002422 volatility | |
|---|---|
| 002422 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 002422 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002422's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 19,798 | Sichuan Liu | www.kelun.com |
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers infusion products; oral medication and other dosage form; plastic ampoule and powder liquid dual chamber infusion bag; medical devices, such as infusion set, injection syringes, detained needles, nebulizer, and blood sampling; and over-the-counter products. The company was founded in 1996 and is based in Chengdu, the People's Republic of China.
Sichuan Kelun Pharmaceutical Co., Ltd. Fundamentals Summary
| 002422 fundamental statistics | |
|---|---|
| Market cap | CN¥50.16b |
| Earnings (TTM) | CN¥2.96b |
| Revenue (TTM) | CN¥22.50b |
16.9x
P/E Ratio2.2x
P/S RatioIs 002422 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002422 income statement (TTM) | |
|---|---|
| Revenue | CN¥22.50b |
| Cost of Revenue | CN¥10.85b |
| Gross Profit | CN¥11.65b |
| Other Expenses | CN¥8.68b |
| Earnings | CN¥2.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 51.76% |
| Net Profit Margin | 13.17% |
| Debt/Equity Ratio | 19.7% |
How did 002422 perform over the long term?
See historical performance and comparison